Phase-1 Molecular Toxicology Inc. has announced a large collaborative research agreement with Boehringer Ingelheim Pharmaceuticals Inc. to develop diagnostic technologies to identify which patients will suffer from adverse reactions to drugs prior to treatment. Spencer Farr, Ph.D. CEO of Phase-1 had this to say about the collaboration with Boehringer Ingelheim Pharmaceuticals: “We believe that this Read more about Phase-1 Molecular Toxicology To Develop Diagnostic Technologies[…]